T Cell Therapy of Opportunistic Cytomegalovirus Infection

This study tests whether infusing CMV-specific T cells — immune cells trained to fight cytomegalovirus (CMV) — can help stem cell transplant recipients who develop a CMV infection that does not respond to standard antiviral medications. CMV can be life-threatening in people with weakened immune systems after a transplant. You may be eligible if: - You have received an allogeneic (donor) stem cell transplant at least 30 days ago - You have documented CMV infection or reactivation with a viral load above 1,000 copies/mL, and/or CMV-related symptoms - Standard antiviral treatment (ganciclovir, valganciclovir, or foscarnet) has not worked, caused side effects, or your CMV has come back a second time - You are aged 3 months or older - You are willing to use contraception if applicable You may NOT be eligible if: - You are pregnant or breastfeeding - You have active moderate-to-severe graft-versus-host disease (GVHD) or require high-dose steroids - You have received antithymocyte globulin within the past 28 days - You have a viral infection other than CMV that is opportunistic Talk to your doctor to see if this trial is right for you.